Investment Thesis
ProtoKinetix is in critical financial distress with only $607 in cash reserves against $45M in operating losses and zero revenue generation. The company's current ratio of 0.03x indicates severe insolvency with virtually no ability to meet near-term obligations. Unless immediate funding materializes, the company faces imminent financial failure.
Strengths
- Minimal long-term debt ($0) reduces liability burden
- Pharmaceutical sector allows for R&D losses in development stage
- Small asset base could theoretically be recapitalized through equity funding
Risks
- Cash reserves of $607 are critically insufficient for operations or obligations
- Current ratio of 0.03x indicates severe liquidity crisis and insolvency
- Zero revenue with $24.9M operating losses is unsustainable burn rate
- Negative operating cash flow of -$135.9K indicates ongoing value destruction
- No insider trading activity suggests lack of confidence or abandoned operations
Key Metrics to Watch
- Cash position (imminent insolvency concern)
- Revenue generation initiation and trajectory
- Operating cash flow trend
- Dilution from emergency equity financing
Financial Metrics
Revenue
0.0
Net Income
-273.7K
EPS (Diluted)
$0.00
Free Cash Flow
-135.9K
Total Assets
477.6K
Cash
607.0
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-109.3%
ROA
-57.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.03x
Quick Ratio
0.03x
Debt/Equity
0.00x
Debt/Assets
9.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T08:18:20.600588 |
Data as of: 2025-09-30 |
Powered by Claude AI